$45 Million raised by Helaina in Series B funding with the intention to accelerate the commercialization of human bioactive proteins

Image courtesy of Helaina.

Biotechnology company, Helaina, disclosed in a recent press release (1), that the establishment had raised $45 million in Series B funding. Helaina is planning to utilize this new funding to advance their product called effera™ Human Lactoferrin, which is an ingredient that helps with healthy aging, supporting women’s health, and active nutrition (1). According to the press release (1), effera™ assists with a balanced immune response, metabolism, supporting iron homeostasis, and encourages a beneficial microbiome. Helaina is offering effera™ “to consumer brands and through strategic distribution partners” and will soon be found in a variety of products from companies such as, The Feed, Healthgevity, Kroma Wellness, Mitsubishi International Food Ingredients, Inc., and Levelle Nutrition (1).

“This infusion of new capital marks the next phase of growth for Helaina in which we are accelerating the availability of our first ingredient through new partnerships – the result of years of work to drive innovation and scientific rigor within nutrition,” Laura Katz, CEO and Founder, Helaina, mentioned (1). “At this pivotal moment in our company’s journey, we’re proud to partner with Avidity Partners, an investment firm with an outstanding reputation for supporting best-in-class biotechnology companies rooted in clinically-backed science.”

In 2019, Katz founded Helaina, “saw opportunity to leverage precision fermentation to set a new standard for nutrition focused on vitality for all ages”, (1). Helaina possesses a bioactive protein pipeline with the intention to help improve human healthspans (1). Future plans for the biotechnology company are to offer an infant formula product.

Jacob Garfield, Managing Director at Avidity Partners said (1), “We are thrilled to support Helaina’s innovative approach to nutrition, which aligns with pressing health and wellness priorities, from immune system support to fostering a balanced gut microbiome.” Garfield further added, “We are confident that Helaina’s technology and business model are well positioned to meet the growing demand for high quality nutritional ingredients that promote vitality across all age groups.”

Reference

1. Helaina raises $45 million in Series B funding to accelerate the commercialization of human bioactive proteins starting with efferaTM human lactoferrin https://www.biospace.com/press-releases/helaina-raises-45-million-in-series-b-funding-to-accelerate-the-commercialization-of-human-bioactive-proteins-starting-with-effera-human-lactoferrin (accessed Sep 26, 2024).